Pharmesis International Ltd
BFK
Company Profile
Business description
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution. The company derives revenue from the sale of medicines to domestic customers in China.
Contact
5 Kallang Sector
No. 03-02
Singapore349279
SGPT: +65 68460766
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
stocks
Better times ahead for these cheap ASX shares?
Our analysts think the outlook looks fairly good for these two undervalued and unloved ASX dividend payers.
video
ASX dividend stocks for 2025
With dividend yields at 25-year lows, it's time to rethink ASX stocks for income according to James Gruber.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,713.70 | 43.00 | -0.49% |
| CAC 40 | 8,206.56 | 17.43 | 0.21% |
| DAX 40 | 22,844.50 | 46.41 | 0.20% |
| Dow JONES (US) | 44,556.34 | 10.26 | 0.02% |
| FTSE 100 | 8,766.73 | 1.28 | -0.01% |
| HKSE | 22,884.96 | 91.85 | -0.40% |
| NASDAQ | 20,041.26 | 14.49 | 0.07% |
| Nikkei 225 | 39,105.99 | 164.41 | -0.42% |
| NZX 50 Index | 13,037.50 | 13.62 | -0.10% |
| S&P 500 | 6,129.58 | 14.95 | 0.24% |
| S&P/ASX 200 | 8,432.60 | 48.40 | -0.57% |
| SSE Composite Index | 3,342.48 | 17.99 | 0.54% |